Sino Biopharmaceutical (OTCMKTS:SBMFF – Get Free Report) will likely be issuing its results after the market closes on Wednesday, August 19th. Analysts expect the company to post earnings of $0.0177 per share and revenue of $2.8412 billion for the quarter.
Sino Biopharmaceutical Stock Performance
OTCMKTS:SBMFF opened at $0.61 on Monday. Sino Biopharmaceutical has a 1 year low of $0.59 and a 1 year high of $1.24. The stock’s fifty day moving average price is $0.62 and its two-hundred day moving average price is $0.72.
Sino Biopharmaceutical Company Profile
Sino Biopharmaceutical Limited (OTCMKTS: SBMFF) is a Hong Kong–incorporated investment holding company principally engaged in the pharmaceutical sector. Founded in 2000 and listed on the Hong Kong Stock Exchange in 2006, the company has developed an integrated business model that spans research and development, manufacturing and commercialization of healthcare products. Through its subsidiaries, Sino Biopharmaceutical focuses on enhancing China’s domestic pharmaceutical infrastructure while expanding its footprint across key therapeutic areas.
The company’s product portfolio is organized into three core segments: infusion solutions, small-molecule synthetic pharmaceuticals and innovative biologics.
Featured Stories
- Five stocks we like better than Sino Biopharmaceutical
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Receive News & Ratings for Sino Biopharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sino Biopharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
